Inve US ▾
DNDNLI

Denali Therapeutics (DNLI) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 6, 2026

Source: earnings call transcript

Executive summary

Denali Therapeutics Q2 FY26 — AVLAYAH Launch and Pipeline Advancement

Denali Therapeutics reported a transformative quarter, marked by the successful initial launch of AVLAYAH, its first commercial product, which exceeded early demand expectations. The company also significantly advanced its Alzheimer's disease pipeline with two new clinical programs and strengthened its financial position through a priority review voucher sale. Management emphasized the validation of its transport vehicle platform and its strategy to leverage this for future growth across rare genetic and neurodegenerative diseases.

Highlights

5

  • AVLAYAH generated $3.6 million in net product revenue in its first full commercial quarter.

  • Pro forma cash, cash equivalents, and marketable securities exceeded $1.1 billion after the Priority Review Voucher sale.

  • Commercial policies covering over 50% of lives for AVLAYAH were established by the end of Q2 FY26.

  • DNL628 (tau) and DNL921 (Abeta) advanced into clinical development for Alzheimer's disease.

  • DNL593 received Orphan Drug Designation for FTD-GRN.

Concerns

2

  • DNL593 data readout for FTD-GRN delayed to H1 2027 from prior expectation of end of year 2026.

  • Intrathecal tau therapies may not achieve uniform distribution throughout the brain and have other limitations.

Guidance & targets

CategoryTargetConfidence
AVLAYAH Net Product Revenue
$10 million to $12 million
high materiality
High
DNL593 FTD-GRN Data Readout
Data in the first half of 2027
medium materiality
High
DNL628 Alzheimer's Disease Initial Clinical Biomarker Data
Initial clinical biomarker data in the first half of 2027
high materiality
High
DNL921 Alzheimer's Disease Initial Safety and Clinical Proof of Concept Data
Initial safety and clinical proof of concept data in 2027
high materiality
High
AVLAYAH COMPASS Phase II/III Study Completion
End of next year
medium materiality
High
DNL126 Potential Launch
Potential launch in 2027
medium materiality
Medium
AVLAYAH Clinical Trial Patient Conversion to Commercial
All clinical trial patients to be able to convert to commercial patients by the end of this year
low materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
AVLAYAH (Hunter Syndrome)
First full commercial quarter for AVLAYAH, exceeding initial demand expectations. Strong physician awareness and family engagement, with rapid payer access.
Eligible US patients: 375Commercial policies covering lives: >50%State Medicaid programs covering: 14Families reached by webinars/services: >100
$3.6 million———

Deals & partnerships

Takeda Regained full ownership and control of DNL593 program.

Denali regained full ownership and control of the DNL593 program from Takeda earlier this year.

Risks & headwinds

Uneven distribution of intrathecally administered antisense oligonucleotides

uneven exposure across brain regions

Mitigation:Denali's OTV delivery uses the capillary network to distribute the antisense oligo broadly across the brain and spinal cord, aiming for uniform distribution.

Modest efficacy and ARIA risk with currently available anti-amyloid antibodies

modest efficacy and the risk of amyloid-related imaging abnormalities, or ARIA

Mitigation:DNL921 is designed to improve plaque engagement while reducing ARIA potential and peripheral immune activation through its transport vehicle-enabled delivery.

Variability in time from patient interest to infusion for AVLAYAH early in launch

huge variability in the time between patients expressing interest to when they actually get infused

Mitigation:Management expects the timeline to become more efficient as payer coverage expands and treatment centers gain experience with AVLAYAH.

What to watch in Q3 FY26

AVLAYAH Net Product Revenue

Q3 FY26
Current $3.6 million
Target $10 million to $12 million

Why it matters

Indicates the early trajectory and adoption rate of Denali's first commercial product.

Given the pace of adoption, expanding access, and continued strong execution, we expect Q3 net product revenue to be in the range of $10 million to $12 million.

Find out whether DNLI delivers this. Inve re-checks your case every morning.

Q&A highlights

What factors give confidence for next quarter's AVLAYAH guidance, and can the growth trajectory continue? Will OpEx guidance be provided?

Management expressed confidence in AVLAYAH's Q3 guidance due to high physician awareness, strong family engagement, expanding payer coverage (>50% commercial lives), and successful medical exceptions. OpEx remained flat YoY despite launch prep and new programs; full-year guidance is typically provided at the beginning of the year.

“So given all the dynamics are moving in the right direction, we feel very confident that the momentum will continue.”

asked by Adam Ferrari · answered by Katie Peng

2 min read 6 chapters

Detailed narrative

AVLAYAH Launch Momentum

Denali's first full commercial quarter for AVLAYAH generated $3.6 million in net product revenue, exceeding initial demand expectations. The launch is supported by high physician awareness (80% surveyed aware pre-approval), strong family engagement (over 100 families reached), and rapid payer access, with commercial policies covering over 50% of lives established. The company expects Q3 net product revenue of $10 million to $12 million, driven by continued positive indicators and expanding access.

Transport Vehicle Platform Validation

AVLAYAH's FDA approval and early commercial success serve as the first proof of Denali's transport vehicle platform's ability to deliver biologic medicines across the blood-brain barrier. This platform is central to its strategy for lysosomal storage disorders and neurodegenerative diseases, demonstrating its capability to progress from scientific concept to an approved medicine for patients.

Alzheimer's Disease Pipeline Advancement

Two key Alzheimer's programs, DNL628 (targeting tau) and DNL921 (targeting Abeta), advanced into clinical development, with initial clinical data expected in 2027. Both are designed to improve brain delivery compared to existing approaches. DNL921 aims for better plaque engagement with reduced ARIA risk, while DNL628 targets broad, uniform distribution of antisense oligonucleotides via intravenous administration, addressing limitations of intrathecal delivery.

DNL593 (FTD-GRN) Update

The DNL593 program, now fully owned by Denali after regaining rights from Takeda, received Orphan Drug Designation. The company extended the observation period for the Phase I/II study, with data now expected in H1 2027, to better characterize treatment effects across biomarkers like neurofilament light chain (NfL) and explore a potential biomarker-driven accelerated approval path, leveraging NfL's regulatory precedent in related neurodegenerative diseases.

Financial Strength and Capital Allocation

Denali ended Q2 FY26 with $940 million in cash, cash equivalents, and marketable securities, which increased to over $1.1 billion pro forma after the $195 million sale of a Priority Review Voucher in July. This capital provides flexibility for portfolio investment, including AVLAYAH commercial activities, preparations for DNL126 launch in 2027, advancement of clinical programs, and building capabilities like its Salt Lake City manufacturing facility.

ETV Franchise Expansion

AVLAYAH is positioned as the commercial foundation for a broader enzyme transport vehicle (ETV) franchise across lysosomal storage disorders, including Sanfilippo syndrome, FTD-GRN, Pompe disease, Gaucher disease, and Hurler syndrome. The ERT market is estimated at over $9 billion, and Denali plans to leverage shared scientific expertise, established relationships, and commercial capabilities for future launches, strengthening the infrastructure for the broader ETV franchise.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.